Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:46:58.811Z.
Calculation as of: 2026-10-06T14:46:58.811Z.
Quote observation: 2026-10-06T14:45:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Greenwich LifeSciences, Inc.
Market Cap
$243.95M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.81M
Operating Cash Flow Yield
N/A
TTM Avg
1.55%
3Y Avg
1.55%
5Y Avg
2.54%
Market Cap
$235.77M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.81M
Operating Cash Flow Yield
7.55%
TTM Avg
8.86%
3Y Avg
9.94%
5Y Avg
8.17%
Market Cap
$250.48M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.85M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.77M
Operating Cash Flow Yield
17.62%
TTM Avg
15.21%
3Y Avg
15.21%
5Y Avg
15.21%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $243.95M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 1.55% | 1.55% | 2.54% |
| Invivyd, Inc. (IVVD)vs › | $243.08M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $235.77M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $236.81M | 7.55% | 8.86% | 9.94% | 8.17% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.48M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.85M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.77M | 17.62% | 15.21% | 15.21% | 15.21% |
| BioAge Labs Inc. (BIOA)vs › | $232.73M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
